Beckett N, Peters R, Tuomilehto J, et al. Immediate and late benefits of treating very elderly people with hypertension: results from active treatment.

Slides:

Advertisements

Similar presentations

CONSENSUS: Cooperative North Scandinavian Enalapril Survival Study Purpose To determine whether the ACE inhibitor enalapril reduces mortality in patients.

Advertisements

TROPHY TRial Of Preventing HYpertension. High-normal BP increases CV risk Vasan RS et al. N Engl J Med. 2001;345: Incidence of CV events in women.

Efficacy and safety of angiotensin receptor blockers: a meta-analysis of randomized trials Elgendy IY et al. Am J Hypertens. 2014; doi:10,1093/ajh/hpu209.

CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin.

CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.

Clinical implications. Burden of coronary disease 56 millions deaths worldwide in millions deaths worldwide in % due to CV disease (~ 16.

Pravastatin in Elderly Individuals at Risk of Vascular Disease Presented at Late Breaking Clinical Trials AHA 2002 PROSPER.

Is It the Achieved Blood Pressure or Specific Medications that Make a Difference in Outcome, or Is the Question Moot? William C. Cushman, MD Professor,

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Main results Swedberg K, et al. Lancet. 2010;376(9744):

Copyleft Clinical Trial Results. You Must Redistribute Slides HYVET Trial The Hypertension in the Very Elderly Trial (HYVET)

CARU The HY pertension in the V ery E lderly T rial – latest data Stephen Jackson Professor of Clinical Gerontology King’s Health Partners.

RALES: Randomized Aldactone Evaluation Study Purpose To determine whether the aldosterone antagonist spironolactone reduces mortality in patients with.

WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.

AIRE: Acute Infarction Ramipril Efficacy study Purpose To determine whether the ACE inhibitor ramipril reduces mortality in patients with evidence of heart.

Study Design Scirica BM, Bhatt DL Braunwald et al, Sexagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med

BEST: Beta-blocker Evaluation Survival Trial Purpose To determine whether the β-blocker bucindolol reduces morbidity and mortality in patients with advanced.

Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.

HOPE: Heart Outcomes Prevention Evaluation study Purpose To evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence.

Renal damage occurs in 1 out of 4 hypertensives Adapted from Leoncini et al. J Hypertens. 2008;26:

Background There are 12 different types of medications to lower blood sugar levels in patients with type 2 diabetes. It is widely agreed upon that metformin.

Why fixed-dose combinations in hypertension? Barrios V, Escobar C. Integrated Blood pressure Control. 2010: Combination therapy is needed when.

Objective: To asses the efficacy of hydrochlorothiazide on 24-h blood pressure (BP) control.Methods: Review of all the randomized trials that assessed.

The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. N Engl J Med 2006; available at: End pointActive therapy PlaceboRelative.

Clinical Outcomes with Newer Antihyperglycemic Agents FDA-Mandated CV Safety Trials 1.

CAPRICORN Adverse CV Events (Frequency ≥ 1.5%) in Either Treatment Group (Uptitration Phase)

Guidelines recommend, as first-line treatment for hypertension, a diuretic or the combination of diuretic ± ACE inhibitor. Prevention of Stroke in Patients.

European trial on reduction of cardiac events with perindopril in stable coronary artery disease Presented at European Society of Cardiology 2003 EUROPA.

Rosuvastatin 10 mg n=2514 Placebo n= to 4 weeks Randomization 6weeks3 monthly Closing date 20 May 2007 Eligibility Optimal HF treatment instituted.

Enrollment and Outcomes Duckworth W, et al. N Engl J Med 2009;360:

COPERNICUS: Carvedilol Prospective Randomized Cumulative Survival trial Purpose To assess the effect of carvedilol, a β 1 -, β 2 - and α 1 -receptor blocker,

Journal Club Mallory McClester, PGY-4 August 16, 2013.

The HYpertension in the Very Elderly Trial

Date of download: 6/18/2016 From: Treatment of Anemia in Patients With Heart Disease: A Systematic Review Ann Intern Med. 2013;159(11): doi: /

The HYpertension in the Very Elderly Trial

Flow of Individuals Through the Vitamin E and Vitamin C Components of the Physicians’ Health Study II Howard D. Sesso et al. JAMA 2008;300:

Blood Pressure and Age in Controlling Hypertension

LEADER trial: Primary Outcome

Copyright © 2007 American Medical Association. All rights reserved.

United States Preventive Services Task Force: Recommendations for ABPM

The Anglo Scandinavian Cardiac Outcomes Trial

TNT: Baseline and final LDL cholesterol levels

BENEFIT Trial design: Patients with positive serologic tests for T. Cruzi and cardiomyopathy were randomized to benznidazole 300 mg daily for days.

on behalf of the ASCOT Investigators *Imperial College London, UK

The Hypertension in the Very Elderly Trial (HYVET)

Volume 7, Issue 8, Pages (August 2008)

Management of hypertension in patients with chronic kidney disease

Insights from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)

SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.

Relative risk of major events with atenolol vs placebo

Cardiovascular Disease and CKD: Core Curriculum 2010

Hazard ratios for the composite primary end-point from sub-group analyses of patents presenting with and without an acute coronary syndrome. Hazard ratios.

FOURIER Trial design: Patients with established cardiovascular disease on statin therapy were randomized to evolocumab 140 mg subcutaneous every 2 weeks.

Primary end point in normotensive and hypertensive patients at baseline (events per 100 patient-years of follow-up) Primary end point Nifedipine Placebo.

OSLER Trial design: Patients from five phase 2 trials and seven phase 3 trials with evolocumab were invited to participate in the OSLER extension program,

(p for noninferiority < 0.001)

HOPE-3 Trial design: Patients without known cardiovascular disease, and with an intermediate risk of cardiovascular events, were randomized in a 2 x 2.

Age-Standardized Rates of Death from Any Cause According to the Estimated GFR among 1,120,295 Ambulatory Adults Alan S.Go et al. N Engl J Med 2004; 351:

Entry, Randomization, and Follow-up of Patients in the Hypertension in the Very Elderly Trial Of the 461 patients who did not meet the protocol criteria,

Baseline Characteristics by hs-CRP

MOMENTUM 3 Trial design: Patients with advanced heart failure were randomized to a centrifugal-flow pump (n = 152) vs. an axial-flow pump (n = 142). Results.

Cumulative survival without events during 1 year of follow-up in patients treated with zofenopril (n=1808), placebo (n=951), lisinopril (n=520) or ramipril.

Difference in the risk of MACEs in patients treated with anti–IL17 agents compared with the placebo in RCTs. IL,interleukin; MACEs, major adverse cardiovascular.

EMPA-REG OUTCOME: Cumulative incidence of the primary outcome

Difference in the risk of MACEs in patients treated with anti-IL23 agents compared with the placebo in RCTs. IL, interleukin; MACEs, major adverse cardiovascular.

Illustration of a trial design to help evaluate the clinical accuracy of a test of ischaemia. Illustration of a trial design to help evaluate the clinical.

Difference in the risk of MACEs in patients treated with anti-TNF agents compared with the placebo in RCTs. MACEs, major adverse cardiovascular events;

CIRCUS Trial design: Patients with anterior STEMI were randomized to IV cyclosporine 2.5 mg/kg (n = 475) vs. placebo (n = 495) immediately before coronary.

Hazard ratios for the composite primary end-point from sub-group analyses of patents presenting with and without an acute coronary syndrome. Hazard ratios.

The cumulative incidence curve demonstrated that patients with a sub-optimal LDL-C response to statin therapy were associated with a higher risk of CVD.

Presentation transcript:

Beckett N, Peters R, Tuomilehto J, et al. Immediate and late benefits of treating very elderly people with hypertension: results from active treatment extension to Hypertension in the Very Elderly randomised controlled trial BMJ. 2012;344:d7541 doi: /bmj.d7541 (Published 4 January 2012) HYVET 1-year extension: Immediate and late benefits with indapamide SR ± perindopril in the treatment of hypertensive patients.

HYVET 1-year extension 1 Study protocol 3.1 years on active treatment 1 year on active treatment n= 3845 patients n= 1712 patients Placebo Indapamide SR ± perindopril Indapamide SR ± perindopril Indapamide SR ± perindopril 2.1 years 1-year extension 2.1 years 1. Beckett N, Peters R, Tuomilehto J, et al. BMJ 2012;344:d7541 doi: /bmj.d7541 (Published 4 January 2012) vs.

HYVET 1 Results n= 3845 patients Placebo Indapamide SR ± perindopril 2.1 years Stroke hazard ratio: -39% P =0.05 in favor of the indapamide SR ± perindopril group. Heart failure hazard ratio: -64% P<0.001 in favor of the indapamide SR ± perindopril group. All-cause mortality hazard ratio: -21% P=0.02 in favor of the indapamide SR ± perindopril group. 1. Beckett NS, Peters R, Fletcher AE, et al. N Engl J Med. 2008;358: Cardiovascular events hazard ratio: -34% P<0.001 in favor of the indapamide SR ± perindopril group. Cardiovascular mortality hazard ratio: -23% P=0.06 in favor of the indapamide SR ± perindopril group. vs.

HYVET 1-year extension 1 Study protocol 3.1 years on active treatment 1 year on active treatment n= 3845 patients n= 1712 patients Placebo Indapamide SR ± perindopril Indapamide SR ± perindopril Indapamide SR ± perindopril 1. Beckett N, Peters R, Tuomilehto J, et al. BMJ 2012;344:d7541 doi: /bmj.d7541 (Published 4 January 2012) 2.1 years 1-year extension vs.

No significant difference between the two arms in: - Stroke P= Heart failure P= Cardiovascular events P=0.55 HYVET 1-year extension 1 Results Indapamide SR ± perindopril provides patients with immediate protection against stroke, heart failure, and cardiovascular events These benefits appeared within 1 year of starting treatment Indapamide SR ± perindopril provides patients with immediate protection against stroke, heart failure, and cardiovascular events These benefits appeared within 1 year of starting treatment n= 3845 patients n= 1712 patients Placebo Indapamide SR ± perindopril Indapamide SR ± perindopril Indapamide SR ± perindopril 2.1 years 1-year extension 1. Beckett N, Peters R, Tuomilehto J, et al. BMJ 2012;344:d7541 doi: /bmj.d7541 (Published 4 January 2012) vs.

Indapamide SR ± perindopril provides cumulative time-dependent life-saving benefits, increased over the long term. Total mortality hazard ratio: -52% P =0.02 in favor of the group treated for 3.1 years. Cardiovascular mortality hazard ratio: -81% P =0.03 in favor of the group treated for 3.1 years. n= 3845 patients n= 1712 patients Placebo Indapamide SR ± perindopril Indapamide SR ± perindopril Indapamide SR ± perindopril 2.1 years 1-year extension HYVET 1-year extension 1 Results 1. Beckett N, Peters R, Tuomilehto J, et al. BMJ 2012;344:d7541 doi: /bmj.d7541 (Published 4 January 2012) vs.

Indapamide SR ± perindopril provides cumulative time-dependent life-saving benefits, increased over the long term. HYVET 1-year extension 1 Results 1. Beckett N, Peters R, Tuomilehto J, et al. BMJ 2012;344:d7541 doi: /bmj.d7541 (Published 4 January 2012) Total mortality Cardiovascular mortality P=0.02 P= % -81%